Ezetimibe
Systematic (IUPAC) name
(3R,4S)-1-(4-fluorophenyl)- 3-((3S)-3-(4-fluorophenyl)-3-hydroxypropyl)-4- (4-hydroxyphenyl)-2-azetidinone
Identifiers
CAS number	163222-33-1
ATC code	C10AX09
PubChem	150311
DrugBank	APRD00619
Chemical data
Formula	C24H21F2NO3
Mol. mass	409.4 g.mol-1
SMILES	eMolecules & PubChem
Pharmacokinetic data
Bioavailability	35–65%
Protein binding	>90%
Metabolism	Intestinal wall, hepatic
Half life	19–30 hours
Excretion	Renal 11%, faecal 78%
Therapeutic considerations
Pregnancy cat.	C (Au), C (U.S.)
Legal status	S4 (Au), POM (UK), ℞-only (U.S.)
Routes	Oral

Ezetimibe (pronounced /ɛˈzɛtəmɪb/) is an anti-hyperlipidemic medication which is used to lower cholesterol levels. It acts by decreasing cholesterol absorption in the intestine. It may be used alone when other cholesterol-lowering medications are not tolerated, or together with statins (e.g. ezetimibe/simvastatin) when cholesterol levels are unable to be controlled on statins alone. It is marketed by Schering-Plough and Merck under the trade names Ezetrol, Zetia and Ezemibe. Ezetimibe was originally discovered by a team of four Schering-Plough research chemists: Drs. Stuart B. Rosenblum, Duane A. Burnett, John W. Clader and Brian A. McKittrick.